UX003
UX003-CL203
Phase 3 small_molecule completed
Quick answer
UX003 for Sly Syndrome is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Sly Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed